Quantcast
Last updated on April 25, 2014 at 5:50 EDT

Latest WuXi AppTec Stories

2013-10-30 16:25:19

SHANGHAI and TAIPEI, Oct. 30, 2013 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it had completed a cell culture capacity expansion, including two 2000L disposable bioreactors that are ready for cGMP manufacturing. Previously WuXi AppTec had built a state-of-the-art cGMP biologics manufacturing facility with two cell...

2013-10-16 12:24:43

SHANGHAI, Oct. 16, 2013 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that its genomics clinical laboratory in Shanghai has successfully passed the survey by the Centers for Medicare and Medicaid Services of the U.S. Department of Health and Human Services relating to CLIA (Clinical Laboratory Improvement Amendments)...

2012-10-19 07:23:32

SHANGHAI, Oct. 19, 2012 /PRNewswire/ -- WuXi AppTec hosted an inaugural Global Monoclonal Antibody Summit in conjunction with the startup of its cGMP biologics manufacturing facility in the city of Wuxi on October 10-12, 2012. Attending the event were executives from global pharmaceutical and biotech companies, scientists and researchers in biologics and officials from the Chinese central and local governments. First cGMP Biologics Facility in China WuXi AppTec has invested substantially in...

2012-09-10 02:28:32

GAITHERSBURG, Md. and SHANGHAI, Sept. 10, 2012 /PRNewswire/ -- MedImmune, the global biologics arm of AstraZeneca, and WuXi AppTec, a leading research and development outsourcing company, today announced that they have formed a joint venture to develop and commercialize MEDI5117, a novel biologic for autoimmune and inflammatory diseases, in China. MedImmune will provide technical and development expertise, while WuXi AppTec will provide local regulatory, manufacturing, pre-clinical and...

2011-08-23 08:00:00

SHANGHAI, Aug. 23, 2011 /PRNewswire-Asia/ -- WuXi AppTec announced today that its Bioanalytical Services (BAS) unit had received a certificate of Good Laboratory Practice (GLP) from the Organization for Economic Cooperation and Development (OECD) and the European Union (EU). The certificate states that WuXi's BAS facility in Shanghai is able to carry out ADME (absorption, distribution, metabolism, and excretion) studies, toxicokinetic and pharmacokinetic studies, and hERG assay and...

2011-06-16 03:14:00

SHANGHAI, June 16, 2011 /PRNewswire-Asia/ -- WuXi AppTec announced today that it has been selected as one of the Top Ten Outsourcing Enterprises in China for 2011 by China's Ministry of Commerce. The list was announced at China's Fourth Annual International Service Outsourcing Cooperation Conference, held in Nanjing on June 10, 2011. Dr. Ge Li, Chairman and Chief Executive Officer of WuXi AppTec, was named a Top Ten Contributor to China's Outsourcing Industry. The conference was hosted...

2010-11-08 12:00:00

SHANGHAI, Nov. 8, 2010 /PRNewswire/ -- Chemical Abstracts Service (CAS), the world's authority for chemical information, announced today that WuXi AppTec, the leading China-based contract research organization (CRO), has signed a contract to provide SciFinder for all scientists within their organization. In 2009, a CAS analysis of chemical literature showed that China led all nations in chemical patent publications and was surging in output of journal literature. WuXi AppTec is convincing...

2010-05-13 07:00:00

SHANGHAI, May 13 /PRNewswire-Asia/ -- WuXi AppTec (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, is honored to have Prof. Eric N. Jacobsen, who is the Sheldon Emery Professor of Chemistry in the Department of Chemistry and Chemical Biology at Harvard University, as a WuXi AppTec Science Seminar Series lecturer to share his experience and expertise with our company's...

2009-10-29 20:40:00

SHANGHAI, Oct. 30 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company, with operations in China and the United States, today announced that it had received the 2009 Excellence Award from Schering-Plough. (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ) The award recognizes WuXi's contributions to Schering-Plough's success in a range of research...

2009-03-31 07:10:00

SHANGHAI, March 31 /PRNewswire-Asia/ -- WuXi AppTec announced today that its Bioanalytical Services (BAS) unit had been inspected by the U.S. Food and Drug Administration (FDA) without the issuance of a Form 483, which is used to report any non compliance issues after a site inspection. (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ) WuXi's Bioanalytical Services (BAS) was established in 2005. BAS provides Good Laboratory Practice (GLP)-compliant services to...